Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationGuidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Jaff, M. R., McMurtry, M. S., Archer, S. L., Cushman, M., Goldenberg, N., Goldhaber, S. Z., Jenkins, J. S., Kline, J. A., Michaels, A. D., Thistlethwaite, P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214914f · Cited by 2,229
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
“…approaches to establish the most appropriate range for different indications, as follows: (1) randomized trials in which patients are assigned to two different target ranges 142–145, 152, 153 ; (2 ) indirect Fixed minidose warfarin (1 mg daily) has been evaluated in a number of clinical settings.”
BackgroundSelf-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationAgeno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Bates, S. M., Greer, I. A., Middeldorp, S., Veenstra, D. L., Prabulos, A.-M., & Vandvik, P. O. (2012) · Chest · doi:10.1378/chest.11-2300 · Cited by 1,525
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationEvidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,061
Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., & Radford, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.017 · Cited by 1,008
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Self-citationThe PREPIC Study Group (2005) · Circulation · doi:10.1161/circulationaha.104.512834 · Cited by 931
A New Risk Scheme to Predict Warfarin-Associated Hemorrhage
Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Singer, D. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.031 · Cited by 852
Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Self-citationRivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Self-citationHemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Self-citationClinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632
Kyrle, P. A., & Eichinger, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71880-8 · Cited by 616
d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054444 · Cited by 622
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Hull, R. D., Pineo, G. F., Brant, R. F., Mah, A. F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M.-C., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.022 · Cited by 607
Self-citationAcute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-Up Study
Plessier, A., Darwish-Murad, S., Hernandez-Guerra, M., Consigny, Y., Fabris, F., Trebicka, J., Heller, J., Morard, I., Lasser, L., Langlet, P., et al. (2010) · Hepatology · doi:10.1002/hep.23259 · Cited by 597
Guidelines on oral anticoagulation with warfarin – fourth edition
Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S., Makris, M., & British Committee for Standards in Haematology (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08753.x · Cited by 586
“For patients who require anticoagulation beyond 3 months, it is not recommended to lower the target range after 3 months as this has been shown to offer poorer efficacy with comparable bleeding rates (Kearon et al, 2003; Ridker et al, 2003).”
BackgroundRodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Self-citationGenetic Determinants of Response to Warfarin during Initial Anticoagulation
Schwarz, U. I., Ritchie, M. D., Bradford, Y., Li, C., Dudek, S. M., Frye-Anderson, A., Kim, R. B., Roden, D. M., & Stein, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708078 · Cited by 577
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., & Schulman, S. (2004) · Chest · doi:10.1378/chest.126.3_suppl.287s · Cited by 515
Self-citationEffect of Study Setting on Anticoagulation Control
van Walraven, C., Jennings, A., Oake, N., Fergusson, D., & Forster, A. J. (2006) · Chest · doi:10.1378/chest.129.5.1155 · Cited by 487
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
Schulman, S., Wåhlander, K., Lundström, T., Clason, S. B., & Eriksson, H. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030104 · Cited by 454
TOSETTO, A., IORIO, A., MARCUCCI, M., BAGLIN, T., CUSHMAN, M., EICHINGER, S., PALARETI, G., POLI, D., TAIT, R. C., & DOUKETIS, J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04735.x · Cited by 443
Management of Antiphospholipid Antibody Syndrome: A Systematic Review
Lim, W., Crowther, M. A., & Eikelboom, J. W. (2006) · JAMA · doi:10.1001/jama.295.9.1050 · Cited by 448
“Three prospective studies suggest that there is an increased risk of recurrence, ranging from 10% to 67% per year.(26,48,49) In a large prospective study,(26) 412 patients with a first episode of venous thromboembolism who completed 6 months of anticoagulation were tested for aCL and followed up prospectively after an…”
BackgroundSelf-citationSelf-monitoring of oral anticoagulation: a systematic review and meta-analysis
Heneghan, C., Alonso-Coello, P., Garcia-Alamino, J., Perera, R., Meats, E., & Glasziou, P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68139-7 · Cited by 438
Chronic Thromboembolic Pulmonary Hypertension
Piazza, G., & Goldhaber, S. Z. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910203 · Cited by 410
Acute Pulmonary Embolism: Part I: Epidemiology, Pathophysiology, and Diagnosis
Goldhaber, S. Z., & Elliott, C. G. (2003) · Circulation · doi:10.1161/01.cir.0000097829.89204.0c · Cited by 406
Mazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., Brekelmans, M. P. A., Büller, H. R., Elias, A., Farge, D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx003 · Cited by 402
Guidelines on oral anticoagulation (warfarin): third edition – 2005 update
Baglin, T. P., Keeling, D. M., Watson, H. G., & the British Committee for Standards in Haematology (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05856.x · Cited by 392
Venous Thromboembolism: Advances in Diagnosis and Treatment
Tritschler, T., Kraaijpoel, N., Le Gal, G., & Wells, P. S. (2018) · JAMA · doi:10.1001/jama.2018.14346 · Cited by 357
Self-citationBoutitie, F., Pinede, L., Schulman, S., Agnelli, G., Raskob, G., Julian, J., Hirsh, J., & Kearon, C. (2011) · BMJ · doi:10.1136/bmj.d3036 · Cited by 371
“Strengths of our analysis that increase the precision and validity of its findings are that we included data from a large number of participants, baseline variables were recorded at enrolment rather than retrospectively, the time of stopping anticoagulant treatment was well documented, participants were followed prosp…”
ResultSelf-citationNicolaides, A., Kakkos, S., Baekgaard, N., Comerota, A., de Maeseneer, M., Eklof, B., Giannoukas, A., Lugli, M., Maleti, O., Mansilha, A., et al. (2020) · International Angiology · doi:10.23736/s0392-9590.20.04388-6 · Cited by 366
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
Self-citationGoldhaber, S. Z. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16004-2 · Cited by 348
Baker, R. I., Coughlin, P. B., Salem, H. H., Gallus, A. S., Harper, P. L., & Wood, E. M. (2004) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06407.x · Cited by 309
JCS Joint Working Group (2011) · Circulation Journal · doi:10.1253/circj.cj-88-0010 · Cited by 306
Guyatt, G. H., Akl, E. A., Crowther, M. A., Gutterman, D. D., & nemann, H. J. S. (2013) · Cited by 309
Self-citationDuration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
Kearon, C., & Akl, E. A. (2014) · Blood · doi:10.1182/blood-2013-12-512681 · Cited by 279
Self-citationLópez, J. A., Kearon, C., & Lee, A. Y. Y. (2004) · Hematology · doi:10.1182/asheducation-2004.1.439 · Cited by 272
Self-citationSelf-monitoring and self-management of oral anticoagulation
Heneghan, C. J., Garcia-Alamino, J. M., Spencer, E. A., Ward, A. M., Perera, R., Bankhead, C., Alonso Coello, P., Fitzmaurice, D., Mahtani, K. R., & Onakpoya, I. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003839.pub3 · Cited by 256
Treatment of Deep-Vein Thrombosis
Bates, S. M., & Ginsberg, J. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp031676 · Cited by 265
Self-citationKearon, C., Ginsberg, J. S., Julian, J. A., Douketis, J., Solymoss, S., Ockelford, P., Jackson, S., Turpie, A. G., MacKinnon, B., Hirsh, J., et al. (2006) · JAMA · doi:10.1001/jama.296.8.935 · Cited by 259
Self-citationSpencer, F. A., Emery, C., Joffe, S. W., Pacifico, L., Lessard, D., Reed, G., Gore, J. M., & Goldberg, R. J. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0378-3 · Cited by 251
“In contrast to data obtained in the context of recent randomized clinical trials of VTE treatment in which the occurrence of major bleeding episodes approximates 1% at 3–6 months after trial enrollment [18, 19, 21], the cumulative incidence of major bleeding in our study was approximately 8% in the month following an…”
ResultCouturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., Provost, K., dit Sollier, C. B., Presles, E., Castellant, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.7046 · Cited by 249
Care of Patients Receiving Long-Term Anticoagulant Therapy
Schulman, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp025373 · Cited by 249
Treatment of Venous Thromboembolism
Wells, P. S., Forgie, M. A., & Rodger, M. A. (2014) · JAMA · doi:10.1001/jama.2014.65 · Cited by 237
Self-citationAssessing bleeding risk in patients taking anticoagulants
Shoeb, M., & Fang, M. C. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0899-7 · Cited by 228
Prandoni, P., Prins, M. H., Lensing, A. W. A., Ghirarduzzi, A., Ageno, W., Imberti, D., Scannapieco, G., Ambrosio, G. B., Pesavento, R., Cuppini, S., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00003 · Cited by 232
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-013-0014-6 · Cited by 201
Diagnosis and treatment of deep-vein thrombosis
Scarvelis, D., & Wells, P. S. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060366 · Cited by 205
“A large randomized trial has shown that low-intensity anticoagulation therapy is less effective than standard anticoagulation therapy at preventing recurrent thrombosis and does not lower the risk of bleeding.(52) Therefore, low-intensity therapy is not recommended.”
BackgroundSelf-citationManagement of Venous Thromboembolism: A Systematic Review for a Practice Guideline
Segal, J. B., Streiff, M. B., Hofmann, L. V., Thornton, K., & Bass, E. B. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-3-200702060-00150 · Cited by 214
Veeger, N. J. G. M., Piersma‐Wichers, M., Tijssen, J. G. P., Hillege, H. L., & van der Meer, J. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05348.x · Cited by 207
“It is emphasized that the patients reported by Ridker et al (2003) and Kearon et al (2003) differed from the patients in our study.”
InfluentialKAHN, S. R., KEARON, C., JULIAN, J. A., MACKINNON, B., KOVACS, M. J., WELLS, P., CROWTHER, M. A., ANDERSON, D. R., VAN NGUYEN, P., DEMERS, C., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01216.x · Cited by 203
Self-citationSiragusa, S., Malato, A., Anastasio, R., Cigna, V., Milio, G., Amato, C., Bellisi, M., Attanzio, M. T., Cormaci, O., Pellegrino, M., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131656 · Cited by 196
Castellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193
Self-citationNicolaides, A., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., Myers, K., Samama, M., Fletcher, J., Kalodiki, E., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612474840 · Cited by 185
Self-citationSteiner, T., Böhm, M., Dichgans, M., Diener, H.-C., Ell, C., Endres, M., Epple, C., Grond, M., Laufs, U., Nickenig, G., et al. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0560-7 · Cited by 183
Does thrombophilia testing help in the clinical management of patients?
Middeldorp, S., & Van Hylckama Vlieg, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07339.x · Cited by 177
“…was investigated in a trial comparing prolonged anticoagulant treatment with vitamin K antagonists with a low intensity (International Normalized Ratio below 2Æ0) and conventional intensity in patients after a first episode of venous thrombosis, with and without thrombophilia (Kearon et al, 2003).”
Oake, N., Jennings, A., Forster, A. J., Fergusson, D., Doucette, S., & van Walraven, C. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080171 · Cited by 172
“1 5 10 15 20 25 30 35 40 45 50 55 60 65 160 International normalized ratio < 2 3–5 > 5 Van Walraven et al.6 Kearon et al.28 EAFT36 Azar et al.39 Palareti et al.38 Casais et al.40 Hutten et al.25 Tangelder et al.34 Torn et al.35 Yasaka et al.27 Andersen et al.37 Poli et al.33 Cheung et al.29 Chimowitz et al.32 Hylek et…”
BackgroundInfluentialSecondary Prophylaxis with Warfarin for Venous Thromboembolism
Büller, H. R., & Prins, M. H. (2003) · New England Journal of Medicine · doi:10.1056/nejme038112 · Cited by 172
Venous thromboembolism in the elderly: A community-based perspective
Gore, J. M., Lessard, D., Emery, C., Pacifico, L., Reed, G., Gurwitz, J. H., Goldberg, R. J., & Spencer, F. A. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-04-0255 · Cited by 164
“The rates observed in our study are between 3-4 fold higher than those observed in recent trials of VTE therapy [8-10].”
ResultOptimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal
Odén, A., Fahlén, M., & Hart, R. G. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2004.11.025 · Cited by 163
“Aggregate analysis of patients with unprovoked venous thromboembolism suggest that INRs of 1.5—1.9 reduce recurrence by about 75% while INRs of 2.0—3.0 reduce this risk by 90% [16].”
BackgroundInfluentialIntroduction to the Ninth Edition
Guyatt, G. H., Akl, E. A., Crowther, M., Schünemann, H. J., Gutterman, D. D., & Lewis, S. Z. (2012) · Chest · doi:10.1378/chest.11-2286 · Cited by 159
Self-citationSeipin: from human disease to molecular mechanism
Cartwright, B. R., & Goodman, J. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r023754 · Cited by 157
CARRIER, M., RODGER, M. A., WELLS, P. S., RIGHINI, M., & LE GAL, G. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04254.x · Cited by 159
Self-citationGlynn, R. J., Ridker, P. M., Goldhaber, S. Z., Zee, R. Y. L., & Buring, J. E. (2007) · Circulation · doi:10.1161/circulationaha.107.716407 · Cited by 132
International Normalized Ratios (INR): the first 20 years
Poller, L. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00775.x · Cited by 157
Young, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
Cosmi, B., Legnani, C., Tosetto, A., Pengo, V., Ghirarduzzi, A., Testa, S., Prisco, D., Poli, D., Tripodi, A., Marongiu, F., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237354 · Cited by 148
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1094 · Cited by 162
Self-citationChitsike, R. S., Rodger, M. A., Kovacs, M. J., Betancourt, M. T., Wells, P. S., Anderson, D. R., Chagnon, I., Gal, G. L., Solymoss, S., Crowther, M. A., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04872.x · Cited by 154
Self-citationFang, M. C. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6101 · Cited by 144
“33,34 Despite the importance of maintaining warfarin in a therapeutic range, nearly one-half of patients with atrial fibrillation who had stroke despite intention-to-treat with warfarin had inadequate anticoagulation (INR 1.5) and 30% were not actively taking warfarin at the time of their stroke.”
InfluentialFrequency of adverse events in patients with poor anticoagulation: a meta-analysis
Oake, N., Fergusson, D. A., Forster, A. J., & van Walraven, C. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061523 · Cited by 142
Acute Pulmonary Embolism: Part II
Goldhaber, S. Z., & Elliott, C. G. (2003) · Circulation · doi:10.1161/01.cir.0000098427.74047.42 · Cited by 158
Venous Thromboembolism and Atherothrombosis An Integrated Approach
Piazza, G., & Goldhaber, S. Z. (2010) · Circulation · doi:10.1161/circulationaha.110.951236 · Cited by 133
GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE PULMONARY EMBOLISM
Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F. M., Brady, A. J. B., Ferreira, D., Janssens, U., et al. (2009) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2009-5-1-96-111 · Cited by 130
Alfonso, A., Jiménez, D., Capitán, C. F., Prandoni, P., Wells, P. S., Vidal, G., Barillari, G., Monreal, M., Lecumberri, R., & and the RIETE Investigators (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0132 · Cited by 129
Self-citationEvolving use of new oral anticoagulants for treatment of venous thromboembolism
Yeh, C. H., Gross, P. L., & Weitz, J. I. (2014) · Blood · doi:10.1182/blood-2014-03-563056 · Cited by 127
Self-citationPost‐treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality
YOUNG, L., Ockelford, P., Milne, D. G., Rolfe‐Vyson, V., MCKELVIE, S., & HARPER, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02120.x · Cited by 126
Kearon, C., Julian, J. A., Kovacs, M. J., Anderson, D. R., Wells, P., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-06-163279 · Cited by 124
Self-citationLong-Term Management of Patients After Venous Thromboembolism
Kearon, C. (2004) · Circulation · doi:10.1161/01.cir.0000140902.46296.ae · Cited by 134
Self-citationAntithrombotic Agents: New Directions in Antithrombotic Therapy
Chan, N., & Weitz, J. I. (2019) · Circulation Research · doi:10.1161/circresaha.118.313155 · Cited by 132
Self-citationPredicting the risk of venous thromboembolism recurrence
Heit, J. A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23128 · Cited by 130
“With appropriate patient selection and management, the risk of major bleeding can be reduced to 1% per year, or less [74,88,89].”
Stefano, V. D., Vannucchi, A. M., Ruggeri, M., Cervantes, F., Álvarez‐Larrán, A., Iurlo, A., Randi, M. L., Pieri, L., Rossi, E., Guglielmelli, P., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.103 · Cited by 115
Use of anticoagulants in elderly patients: practical recommendations
Righini, M. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4308 · Cited by 133
“36).(18,19) Although hemorrhagic risk was comparable in low-intensity and conventional-intensity regimen groups in the study by Kearon et al(18) the bleeding rates in this study were extremely low in both groups (and different from the usual bleeding rates mentioned in other studies) and probably not representative of…”
Klok, F. A., Kooiman, J., Huisman, M. V., Konstantinides, S., & Lankeit, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00040714 · Cited by 117
Couturaud, F., Schmidt, J., Sanchez, O., Ballerie, A., Sevestre, M., Meneveau, N. F., Bertoletti, L., Connault, J., Benhamou, Y., Constans, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02842-3 · Cited by 118
“Whereas trials evaluating low-dose warfarin did not verify this hypothesis, 16 two randomised trials that tested extended use of reduced-dose and full-dose direct oral anticoagulants found that reduced-dose apixaban was more effective than placebo and possibly as effective as and safer than…”
The Post-thrombotic Syndrome: The Forgotten Morbidity of Deep Venous Thrombosis
Kahn, S. R. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5574-9 · Cited by 113
Self-citationEvolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 125
Self-citation
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.